Plain-English translation of NCT07177300 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The ENHANCE study is testing a better way to use hydroxyurea — a medication that helps reduce pain and complications in children with sickle cell disease — in very young children ages 6 months to 5 years. Researchers will closely monitor how well the medication works, how your child's body handles it, and what it does to protect important organs like the heart, kidneys, and brain. They'll also track growth, development, and long-term health to make sure the medication is safe and effective for young children.
Hydroxyurea is known to help reduce sickle cell complications, but doctors don't fully understand the best way to dose it in very young children or exactly how it protects their organs and development. This study aims to fill those gaps so that treatment can be as effective and safe as possible from the earliest ages.
You likely qualify if…
You likely don't qualify if…
Your child will start hydroxyurea at a dose that is carefully calculated and optimized for them using the latest scientific methods. You'll bring your child to Cincinnati Children's Hospital Medical Center for regular visits where doctors will do blood tests, organ function assessments (including heart, kidney, brain, and eye exams), and growth and development checks. Throughout the study, researchers will track how well the medication is working, how your child's body processes it, and what effects it has — with special attention to protecting important organs and supporting healthy development into puberty.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States